Designing issues in confirmatory adaptive population enrichment trials

Journal of Biopharmaceutical Statistics

Volumn 25, Issue 4, 2015, Pages 651-669

  Wassmer, Gernot ^a,b   Dragalin, Vlad ^a  

^a ICON PLC   (United Kingdom)

^b Institute of Medical Statistics   (Germany)

Author keywords

Adaptive design; Clinical trials; Group sequential tests; Population enrichment; Subgroup selection

Indexed keywords

ADAPTIVE POPULATION ENRICHMENT DESIGN; ARTICLE; BREAST METASTASIS; CONFIDENCE INTERVAL; EFFECT SIZE; HUMAN; METHODOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; SAMPLE SIZE; SEQUENTIAL ANALYSIS; STATISTICAL ANALYSIS; CLINICAL TRIAL (TOPIC); PROCEDURES; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84929381129     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2014.920869     Document Type: Article

References (36)

1. ADDPLAN, Inc., an Aptiv Solutions Company. (2012). ADDPLAN PE Version 6. 0 User Manual. Cologne, Germany: Aptiv Solutions.
2. Alosh, M., Huque, M. F. (2009). A flexible strategy for testing subgroups and overall population. Statistics in Medicine 28:3-23.
3. André, T., Boni, C., Navaro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivero, F., deGramont, A. (2009). Improved overall survival with oxaliplatin, flourouracil, and leucovorin as adjuvant treatment in stage II order III colon cancer in the MOSAIC trial. Journal of Clinical Oncology 27:3109-3116.
4. Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., Esserman, L. (2009). I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology and Therapeutics 86:97-100.
5. Bauer, P., Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18:1833-1848.
6. Bauer, P., Kohne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50:1029-1041.
7. Benda, N., Branson, M., Maurer, W., Friede, T. (2010). Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44:299-315.
8. Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy on oncology. Statistics in Medicine 28:1445-1463.
9. Bretz, F., Konig, F., Brannath, W., Glimm, E., Posch, M. (2009). Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials. Statistics in Medicine 28:1181-1217.
10. Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7878.
11. Friede, T., Parsons, N., Stallard, N. (2012). A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31:4309-4320; correction in 32: 2513-2514.
12. Friede, T., Stallard, N. (2008). A comparison of methods for adaptive treatment selection. Biometrical Journal 50:767-781.
13. Hochberg, Y., Tamhane, A. C. (1987). Multiple Comparison Procedures. New York: Wiley.
14. Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10:347-356.
15. Kelly, P. J., Stallard, N., Todd, S. (2005). An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several. Journal of Biopharmaceutical Statistics 15:641-658.
16. Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55:1286-1290.
17. Maitournam, A., Simon, R. (2005). On the efficiency of targeted clinical trials. Statistics in Medicine 24:329-339.
18. Marcus, R., Peritz, E., Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660.
19. Mehta, C., Gao, P. (2011). Population enrichment designs: Case study of a large multinational trial. Journal of Biopharmaceutical Statistics 21:831-845.
20. Mehta, C., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S.,Ware, J. H. (2009). Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 119:597-605.
21. NAS-REPORT. (2011). Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: The National Academies Press.
22. Parsons, N., Friede, T., Todd, S., Valdes-Marquez, E., Chataway, J., Nicholas, R., Stallard, N. (2012). An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis 56:1150-1160.
23. Posch, M., Konig, F., Branson, M., Brannath, W., Dunger-Baldauf, C., Bauer, P. (2005). Testing and estimating in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 24:3697-3714.
24. Schoenfeld, D. A. (1983). Sample-size formula for the proportional-hazards regression model. Biometrics 39:499-503.
25. Simon, R. (2004). An agenda for clinical trials in the genomic era. Clinical Trials 1:468-470.
26. Spiessens, B., Debois, M. (2010). Adjusted significance levels for subgroup analysis in clinical trials. Contemporary Clinical Trials 31:647-656.
27. Stallard, N., Hamborg, T., Parsons, N., Friede, T. (2014). Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 24:168-187.
28. Temple, R. (1994). Special study designs: early escape, enrichment, studies in non-responders. Communications in Statistics-Theory and Methods 23:499-531.
29. Temple, R. (2005). Enrichment designs: Efficiency in development of cancer treatments. Journal of Clinical Oncology 23:4838-4839.
30. Tournoux-Facon, C., De Ryckee, Y., Tubert-Bitter, P. (2011a). How a new stratified adaptive phase II design could improve targeting population. Statistics in Medicine 30:1555-1562.
31. Tournoux-Facon, C., De Ryckee, Y., Tubert-Bitter, P. (2011b). Targeting population entering phase III trials: A new stratified adaptive phase II design. Statistics in Medicine 30:801-811.
32. Wang, S.-J., Hung, H. M. J., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51:358-374.
33. Wang, S.-J., O'Neill, R., Hung, J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244.
34. Wassmer, G. (1999). Multistage adaptive test procedures based on Fisher's product criterion. Biometrical Journal 41:279-293.
35. Wassmer, G. (2006). Planning and analyzing adaptive group sequential survival trials. Biometrical Journal 48:714-729.
36. Wassmer, G. (2011). On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 21:802-817.